Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RC48 Combined With PD-1 and Radiotherapy as Bladdersparing Therapy in Patients With Muscular Infiltrating Bladder Uroepithelial Carcinoma With Limited HER-2 Expression Following Maximum Electrical Resection or Partial Cystectomy

NCT05979740 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05979740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RC48 Combined With PD-1 and Radiotherapy as Bladdersparing Therapy in Patients With Muscular Infiltrating Bladder Uroepithelial Carcinoma With Limited HER-2 Expression Following Maximum Electrical Resection or Partial Cystectomy
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2023
Completion date
February 13, 2024
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-drug conjugates, her2 expression, muscle invasive bladder cancer, pd-1, radiotherapy